Clinical medicine profile
Domperidone /Esomeprazole
Proton pump inhibitor (PPI)
- Route
- ORAL / IV
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Domperidone] Hypersensitivity to PPIs.
- Caution with rilpivirine and some antivirals (gastric pH). [Esomeprazole] Hypersensitivity to PPIs.
- Caution with rilpivirine and some antivirals (gastric pH).
Precautions
- Use lowest effective dose/shortest duration.
- Long-term: hypomagnesaemia, B12 deficiency, increased GI infection risk, fracture signal, fundic polyps.
- Masking of malignancy — investigate alarm features.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Rare AIN; otherwise minimal renal dosing issues.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Severe hepatic impairment: dose reduction for some agents.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Proton pump inhibitor (PPI)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Gastroesophageal reflux disease (GERD).
Adverse effects
- [From component Domperidone] Raised prolactin concentrations hence likelihood of having gynaecomastia and galactorrhoea
- reduced libido
- hypersensitivity reactions
- hyper- tensive crisis with phaeochromocytoma.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Domperidone, Esomeprazole.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Domperidone): It is a dopamine antagonist, which stimulates gastric emptying, strengthens oesophageal sphincter contractions and enhances small intestinal transit. As an anti-emetic, it acts at chemoreceptor trigger zone hence not effective in vestibular disorders e.g. motion sickness.
1–2 hours; full acid suppression days
24 hours+ (irreversible pump inhibition)
ORAL / IV
(polymorphisms affect levels). Short plasma
but prolonged pharmacodynamic effect.
Pregnancy, lactation & diet
[Domperidone] Often used when indicated; omeprazole has substantial human data — still risk–benefit. [Esomeprazole] Often used when indicated; omeprazole has substantial human data — still risk–benefit.
Generally considered acceptable; infant exposure low.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| ESODOME | SIMBA PHARMACEUTICALS LTD | Coated Tablet | Unavailable |
| ESOFAG D | DAIMA BIASHARA / Wholesale Import | 40MG/30MG CAPS 30*S | KES 834.18Daima Chemist price-list reference ↗ Source date not recorded · verify current price |
| ESOGLAX 40-D | GALAXY PHARMACEUTICAL LIMITED | Capsule, Hard | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.